Foghorn Therapeutics, Inc. (FHTX)
2.085
0.00 (0.00%)
USD |
NASDAQ |
Oct 30, 16:00
2.085
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Cash from Investing (Quarterly) : -2.967M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.967M |
| March 31, 2026 | -17.72M |
| December 31, 2025 | 13.23M |
| September 30, 2025 | 35.57M |
| June 30, 2025 | 33.83M |
| March 31, 2025 | 29.40M |
| December 31, 2024 | 22.29M |
| September 30, 2024 | -61.32M |
| June 30, 2024 | -17.98M |
| March 31, 2024 | 27.10M |
| December 31, 2023 | 37.38M |
| September 30, 2023 | 38.43M |
| June 30, 2023 | 39.13M |
| Date | Value |
|---|---|
| March 31, 2023 | 29.50M |
| December 31, 2022 | -6.507M |
| September 30, 2022 | 46.05M |
| June 30, 2022 | -124.46M |
| March 31, 2022 | -159.41M |
| December 31, 2021 | 9.673M |
| September 30, 2021 | -47.33M |
| June 30, 2021 | 77.09M |
| March 31, 2021 | -3.261M |
| December 31, 2020 | -100.22M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -1.021M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | 0.00 |
| Vaxcyte, Inc. | 147.72M |
| Connect Biopharma Holdings Ltd. | -4.456M |
| Caribou Biosciences, Inc. | 18.94M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.84M |
| Cash from Financing (Quarterly) | -0.022M |
| Free Cash Flow | -84.29M |
| Free Cash Flow Per Share (Quarterly) | -0.2534 |
| Free Cash Flow to Equity (Quarterly) | -19.00M |
| Free Cash Flow to Firm (Quarterly) | -17.89M |
| Free Cash Flow Yield | -62.23% |